Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAiRegenerative MedicineCell TherapyGene Therapy

PUBLISHER: Visiongain | PRODUCT CODE: 2037279

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2037279

Global Cell & Gene Therapy Market Report 2026-2036

PUBLISHED:
PAGES: 424 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5959.50
PDF (Team License - Up to 6 Users)
USD 7055.50
PDF (Site License)
USD 8288.50
PDF (Enterprise License - Includes Free Datasets)
USD 10473.65

Add to Cart

Description

Table of Contents

List of Tables

The global cell & gene therapy market is projected to grow at a CAGR of 17.3% by 2036.

The global Cell & Gene Therapy market is projected to grow from US$25.78 billion in 2026 to US$126.86 billion by 2036, at a CAGR of 17.3%, reflecting strong commercial momentum as advanced therapies move further into mainstream clinical and commercial use.

Growth is powered by the rising global burden of genetic and chronic disease, sustained progress in genomic science, and accelerating clinical adoption of potentially curative therapies across oncology and rare disease indications.

Scientific Advances Powering Market Growth

Breakthroughs in gene editing, viral vector engineering, and cell therapy design are reshaping the competitive landscape of the cell & gene therapy market. Technologies such as CRISPR-based editing and next-generation CAR-T platforms are improving therapeutic precision, manufacturing scalability, and clinical outcomes.

At the same time, advances in production processes and automation are reducing manufacturing complexity and enabling broader commercialisation. The integration of genomic data and personalised medicine approaches is also widening the range of conditions that can be addressed.

Rising Disease Burden Sustaining Demand

The growing global prevalence of genetic and congenital disorders continues to underpin demand for cell & gene therapies. By targeting the underlying biological mechanisms of disease - rather than managing symptoms - these treatments represent a genuinely transformative approach in modern medicine.

Enhanced diagnostics and screening capabilities are enabling earlier identification of genetic conditions, improving patient stratification and accelerating clinical development pipelines.

High Treatment Costs Constraining Access

Upfront therapy costs remain a significant barrier. Many treatments exceed US$2 million per patient, creating affordability challenges for healthcare systems and payers alike.

Reimbursement frameworks are still catching up, with outcomes-based and instalment payment models gaining traction but not yet broadly adopted. Delays in reimbursement decisions and limited treatment infrastructure continue to constrain patient access and slow market uptake.

Trade Flows, Policy Shifts & Supply Chain Pressures

The cell & gene therapy market depends on complex international supply chains for specialised biological materials, reagents, and manufacturing equipment.

U.S. trade tariffs may increase costs for imported inputs and introduce supply chain uncertainty - particularly for smaller biotechnology companies. These pressures can affect development timelines, manufacturing capacity, and overall commercial scalability.

Commercial Implications

  • Cost and pricing pressure: Elevated therapy and input costs are shaping market access dynamics
  • Supply chain shifts: Companies are investing in resilient, localised manufacturing infrastructure
  • Regulatory influence: Approval processes and reimbursement frameworks remain pivotal
  • Competitive positioning: Firms with scalable platforms and strong clinical pipelines are leading

Company Intelligence

The market is intensely competitive, with large pharmaceutical groups and specialist biotechnology firms both pushing the boundaries of innovation.

Leading players are directing investment towards pipeline expansion, strategic alliances, and manufacturing scale-up to strengthen their market positions.

Competitive differentiation is increasingly driven by:

  • Clinical pipeline strength
  • Technology platforms and innovation
  • Manufacturing scalability
  • Regulatory and commercial execution

This report examines how competitive dynamics are evolving and where future value creation will emerge.

Key Questions Answered

  • How is the Cell & Gene Therapy market evolving?
  • What are the key drivers and restraints shaping growth?
  • Which segments and regions will generate the most revenue?
  • How will reimbursement and pricing models evolve?
  • Who are the leading companies and what are their prospects?

Report Scope and Data Coverage

  • Global Cell & Gene Therapy market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across therapy type, indication, vector type, and end-user
  • Regional and national market forecasts
  • Competitive intelligence on leading companies

Covers both quantitative forecasting and qualitative strategic analysis.

Segmentation Framework

By Therapy Type

  • Cell Therapy

Stem Cell Therapy

CAR-T Cell Therapy

TCR-T Cell Therapy

Others

  • Gene Therapy

Gene Augmentation Therapy

Gene Inhibition Therapy

Gene Editing

Others

By Indication

  • Oncology
  • Genetic Disorders
  • Cardiovascular Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Ophthalmic Disorders
  • Others

By Vector Type

  • Viral Vectors
  • Retrovirus
  • Lentivirus
  • Adenovirus
  • AAV
  • Others

Non-viral Vectors

By End-user

  • Hospitals
  • Research Institutes
  • Pharmaceutical Companies
  • Others

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Company Intelligence Coverage

This report includes detailed profiles of leading companies such as:

  • Adaptimmune
  • ALLOGENE THERAPEUTICS
  • Atara Biotherapeutics, Inc.
  • Beam Therapeutics
  • BioMarin
  • Bristol-Myers Squibb Company
  • Catalent, Inc
  • CRISPR Therapeutics
  • Genetix Biotherapeutics Inc.
  • GenScript
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Johnson & Johnson
  • Lonza
  • MeiraGTx Limited
  • Novartis AG
  • Sarepta Therapeutics, Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Vertex Pharmaceuticals Incorporated

Each profile includes:

  • Business overview
  • Financial positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain provides tailored intelligence to support specific business needs, including custom forecasts, competitive benchmarking, and regulatory analysis.

Why This Market Intelligence Matters

  • The Cell & Gene Therapy market is entering a pivotal growth phase, driven by scientific breakthroughs, expanding clinical adoption, and evolving reimbursement frameworks.
  • Organisations with a clear view of these dynamics will be better placed to capture opportunities, manage risk, and strengthen their competitive position.
Show more
Product Code: PHA1385

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Cell & Gene Therapy Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Rising Prevalence of Genetic Disorders Fueling Advanced Therapeutic Adoption
      • 3.3.1.2 Growing Investment in Biotechnology Research Driving Pipeline Innovation Expansion.
      • 3.3.1.3 Increasing Regulatory Approvals, Accelerating Commercialization of Novel Therapies.
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Treatment Costs Limit Patient Accessibility and Market Penetration.
      • 3.3.2.2 Complex Manufacturing Processes Causing Supply Chain Bottlenecks Worldwide.
      • 3.3.2.3 Stringent Regulatory Frameworks are Delaying Product Approvals and Market Entry
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Expanding Healthcare Infrastructure Supporting Advanced Therapy Integration Globally
      • 3.3.3.2 Emerging Collaborations Fostering Rapid Innovation in Personalized Medicine
      • 3.3.3.3 Technological Advancements Enabling Scalable Production of Cell-based Therapies
  • 3.4 U.S. Tariffs: What's the Impact on Global Cell & Gene Therapy Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
      • 3.4.2.1 Why V-Shaped Recovery?
      • 3.4.2.2 Impact from Tariffs
      • 3.4.2.3 Market Dynamics and Demand Recovery
      • 3.4.2.4 Policy and Funding Support
      • 3.4.2.5 Timeframe for Recovery
    • 3.4.3 U-Shaped Recovery Scenario
      • 3.4.3.1 Why U-Shaped Recovery?
      • 3.4.3.2 Impact from Tariffs
      • 3.4.3.3 Market Dynamics and Demand Recovery
      • 3.4.3.4 Policy and Funding Support
      • 3.4.3.5 Timeframe for Recovery
    • 3.4.4 L Shaped Recovery Scenario
      • 3.4.4.1 Why L-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2030) and Long-term (2031-2036) Planning?
    • 3.4.6 Impact of U.S. and China Trade War on Cell & Gene Therapy Market
    • 3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
    • 3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Cell & Gene Therapy Market Analysis by Therapy Type

  • 4.1 Key Findings
  • 4.2 Therapy Type Segment: Market Attractiveness Index
  • 4.3 Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
  • 4.4 Cell Therapy
    • 4.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
    • 4.4.3 Stem Cell Therapy
      • 4.4.3.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 4.4.3.2 Market Share by Region, 2026 & 2036 (%)
    • 4.4.4 CAR-T Cell Therapy
      • 4.4.4.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 4.4.4.2 Market Share by Region, 2026 & 2036 (%)
    • 4.4.5 TCR-T Cell Therapy
      • 4.4.5.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 4.4.5.2 Market Share by Region, 2026 & 2036 (%)
    • 4.4.6 Others
      • 4.4.6.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 4.4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 Gene Therapy
    • 4.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)
    • 4.5.3 Gene Augmentation Therapy
      • 4.5.3.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 4.5.3.2 Market Share by Region, 2026 & 2036 (%)
    • 4.5.4 Gene Inhibition Therapy
      • 4.5.4.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 4.5.4.2 Market Share by Region, 2026 & 2036 (%)
    • 4.5.5 Gene Editing
      • 4.5.5.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 4.5.5.2 Market Share by Region, 2026 & 2036 (%)
    • 4.5.6 Others
      • 4.5.6.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 4.5.6.2 Market Share by Region, 2026 & 2036 (%)

5 Cell & Gene Therapy Market Analysis by Indication

  • 5.1 Key Findings
  • 5.2 Therapy Type Segment: Market Attractiveness Index
  • 5.3 Cell & Gene Therapy Market Size Estimation and Forecast by Indication
  • 5.4 Oncology
    • 5.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Genetic Disorders
    • 5.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Cardiovascular Disorders
    • 5.6.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)
  • 5.7 Neurological Disorders
    • 5.7.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.7.2 Market Share by Region, 2026 & 2036 (%)
  • 5.8 Infectious Diseases
    • 5.8.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.8.2 Market Share by Region, 2026 & 2036 (%)
  • 5.9 Ophthalmic Disorders
    • 5.9.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.9.2 Market Share by Region, 2026 & 2036 (%)
  • 5.10 Others
    • 5.10.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.10.2 Market Share by Region, 2026 & 2036 (%)

6 Cell & Gene Therapy Market Analysis by Vector Type

  • 6.1 Key Findings
  • 6.2 Vector Type Segment: Market Attractiveness Index
  • 6.3 Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
  • 6.4 Viral Vectors
    • 6.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
    • 6.4.3 Retrovirus
      • 6.4.3.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 6.4.3.2 Market Share by Region, 2026 & 2036 (%)
    • 6.4.4 Lentivirus
      • 6.4.4.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 6.4.4.2 Market Share by Region, 2026 & 2036 (%)
    • 6.4.5 Adenovirus
      • 6.4.5.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 6.4.5.2 Market Share by Region, 2026 & 2036 (%)
    • 6.4.6 AAV (Adeno-associated virus)
      • 6.4.6.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 6.4.6.2 Market Share by Region, 2026 & 2036 (%)
    • 6.4.7 Others
      • 6.4.7.1 Market Size by Region, 2026-2036 (US$ Billion)
      • 6.4.7.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Non-viral Vectors
    • 6.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Cell & Gene Therapy Market Analysis by End User

  • 7.1 Key Findings
  • 7.2 End-user Segment: Market Attractiveness Index
  • 7.3 Cell & Gene Therapy Market Size Estimation and Forecast by End-user
  • 7.4 Hospitals
    • 7.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Research Institutes
    • 7.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Pharmaceutical Companies
    • 7.6.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)
  • 7.7 Others
    • 7.7.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 7.7.2 Market Share by Region, 2026 & 2036 (%)

8 Cell & Gene Therapy Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Cell & Gene Therapy Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Cell & Gene Therapy Market Attractiveness Index
  • 9.3 North America Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 9.4 North America Cell & Gene Therapy Market Size Estimation and Forecast by Country
  • 9.5 North America Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
  • 9.6 North America Cell & Gene Therapy Market Size Estimation and Forecast by Indication
  • 9.7 North America Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
  • 9.8 North America Cell & Gene Therapy Market Size Estimation and Forecast by End-user
  • 9.9 U.S. Cell & Gene Therapy Market Analysis
  • 9.10 Canada Cell & Gene Therapy Market Analysis

10 Europe Cell & Gene Therapy Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Cell & Gene Therapy Market Attractiveness Index
  • 10.3 Europe Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 10.4 Europe Cell & Gene Therapy Market Size Estimation and Forecast by Country
  • 10.5 Europe Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
  • 10.6 Europe Cell & Gene Therapy Market Size Estimation and Forecast by Indication
  • 10.7 Europe Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
  • 10.8 Europe Cell & Gene Therapy Market Size Estimation and Forecast by End-user
  • 10.9 Germany Cell & Gene Therapy Market Analysis
  • 10.10 France Cell & Gene Therapy Market Analysis
  • 10.11 UK Cell & Gene Therapy Market Analysis
  • 10.12 Italy Cell & Gene Therapy Market Analysis
  • 10.13 Spain Cell & Gene Therapy Market Analysis
  • 10.14 Russia Cell & Gene Therapy Market Analysis
  • 10.15 Rest of Europe Cell & Gene Therapy Market Analysis

11 Asia Pacific Cell & Gene Therapy Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Cell & Gene Therapy Market Attractiveness Index
  • 11.3 Asia Pacific Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 11.4 Asia-Pacific Cell & Gene Therapy Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
  • 11.6 Asia Pacific Cell & Gene Therapy Market Size Estimation and Forecast by Indication
  • 11.7 Asia Pacific Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
  • 11.8 Asia Pacific Cell & Gene Therapy Market Size Estimation and Forecast by End-user
  • 11.9 Japan Cell & Gene Therapy Market Analysis
  • 11.10 China Cell & Gene Therapy Market Analysis
  • 11.11 India Cell & Gene Therapy Market Analysis
  • 11.12 Australia Cell & Gene Therapy Market Analysis
  • 11.13 South Korea Cell & Gene Therapy Market Analysis
  • 11.14 Singapore Cell & Gene Therapy Market Analysis
  • 11.15 Rest of Asia Pacific Cell & Gene Therapy Market Analysis

12 Latin America Cell & Gene Therapy Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Cell & Gene Therapy Market Attractiveness Index
  • 12.3 Latin America Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 12.4 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by Country
  • 12.5 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
  • 12.6 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by Indication
  • 12.7 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
  • 12.8 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by End-user
  • 12.9 Brazil Cell & Gene Therapy Market Analysis
  • 12.10 Mexico Cell & Gene Therapy Market Analysis
  • 12.11 Argentina Cell & Gene Therapy Market Analysis
  • 12.12 Rest of Latin America Cell & Gene Therapy Market Analysis

13 MEA Cell & Gene Therapy Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Cell & Gene Therapy Market Attractiveness Index
  • 13.3 MEA Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 13.4 MEA Cell & Gene Therapy Market Size Estimation and Forecast by Country
  • 13.5 MEA Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
  • 13.6 MEA Cell & Gene Therapy Market Size Estimation and Forecast by Indication
  • 13.7 MEA Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
  • 13.8 MEA Cell & Gene Therapy Market Size Estimation and Forecast by End-user
  • 13.9 GCC Cell & Gene Therapy Market Analysis
  • 13.10 South Africa Cell & Gene Therapy Market Analysis
  • 13.11 Rest of the MEA Cell & Gene Therapy Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2026
  • 14.2 Strategic Outlook
  • 14.3 Adaptimmune
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2021-2024
      • 14.3.3.2 R&D, 2021-2024
    • 14.3.4 Product Benchmarking
    • 14.3.5 SWOT Analysis
    • 14.3.6 Strategic Outlook
  • 14.4 ALLOGENE THERAPEUTICS
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2021-2024
      • 14.4.3.2 R&D, 2021-2024
    • 14.4.4 Product Benchmarking
    • 14.4.5 SWOT Analysis
    • 14.4.6 Strategic Outlook
  • 14.5 Atara Biotherapeutics, Inc.
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2021-2024
      • 14.5.3.2 R&D, 2021-2024
    • 14.5.4 Product Benchmarking
    • 14.5.5 SWOT Analysis
    • 14.5.6 Strategic Outlook
  • 14.6 Beam Therapeutics
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2021-2024
      • 14.6.3.2 R&D, 2021-2024
    • 14.6.4 Product Benchmarking
    • 14.6.5 SWOT Analysis
    • 14.6.6 Strategic Outlook
  • 14.7 BioMarin
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2021-2025
      • 14.7.3.2 R&D, 2021-2025
      • 14.7.3.3 Regional Market Shares, 2025
    • 14.7.4 Product Benchmarking
    • 14.7.5 SWOT Analysis
    • 14.7.6 Strategic Outlook
  • 14.8 Bristol-Myers Squibb Company
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2021-2025
      • 14.8.3.2 R&D, 2021-2025
      • 14.8.3.3 Regional Market Shares, 2024
      • 14.8.3.4 Business Segment Market Shares, 2024
    • 14.8.4 Product Benchmarking
    • 14.8.5 SWOT Analysis
    • 14.8.6 Strategic Outlook
  • 14.9 Catalent, Inc
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2021-2024
      • 14.9.3.2 Regional Market Shares, 2024
      • 14.9.3.3 Business Segment Market Shares, 2024
    • 14.9.4 Product Benchmarking
    • 14.9.5 SWOT Analysis
    • 14.9.6 Strategic Outlook
  • 14.10 CRISPR Therapeutics
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2021-2025
      • 14.10.3.2 R&D, 2021-2024
    • 14.10.4 Product Benchmarking
    • 14.10.5 SWOT Analysis
    • 14.10.6 Strategic Outlook
  • 14.11 Genetix Biotherapeutics Inc.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Product Benchmarking
    • 14.11.4 SWOT Analysis
  • 14.12 GenScript
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2021-2025
      • 14.12.3.2 Regional Market Shares, 2024
      • 14.12.3.3 Business Segment Market Shares, 2025
    • 14.12.4 Product Benchmarking
    • 14.12.5 SWOT Analysis
    • 14.12.6 Strategic Outlook
  • 14.13 Gilead Sciences, Inc.
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2021-2025
      • 14.13.3.2 R&D, 2021-2025
      • 14.13.3.3 Regional Market Shares, 2025
      • 14.13.3.4 Business Segment Market Shares, 2025
    • 14.13.4 Product Benchmarking
    • 14.13.5 SWOT Analysis
    • 14.13.6 Strategic Outlook
  • 14.14 Intellia Therapeutics, Inc.
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2021-2024
      • 14.14.3.2 R&D, 2021-2024
    • 14.14.4 Product Benchmarking
    • 14.14.5 SWOT Analysis
    • 14.14.6 Strategic Outlook
  • 14.15 Johnson & Johnson
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Financial Analysis
      • 14.15.3.1 Net Revenue, 2021-2025
      • 14.15.3.2 R&D, 2021-2025
      • 14.15.3.3 Regional Market Shares, 2025
      • 14.15.3.4 Business Segment Market Shares, 2025
    • 14.15.4 Product Benchmarking
    • 14.15.5 SWOT Analysis
    • 14.15.6 Strategic Outlook
  • 14.16 Lonza
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Financial Analysis
      • 14.16.3.1 Net Revenue, 2021-2024
      • 14.16.3.2 R&D, 2021-2024
      • 14.16.3.3 Regional Market Shares, 2024
      • 14.16.3.4 Business Segment Market Shares, 2024
    • 14.16.4 Product Benchmarking
    • 14.16.5 SWOT Analysis
    • 14.16.6 Strategic Outlook
  • 14.17 MeiraGTx Limited
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2021-2024
      • 14.17.3.2 R&D, 2021-2024
    • 14.17.4 Product Benchmarking
    • 14.17.5 SWOT Analysis
    • 14.17.6 Strategic Outlook
  • 14.18 Novartis AG
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Financial Analysis
      • 14.18.3.1 Net Revenue, 2021-2025
      • 14.18.3.2 R&D, 2021-2025
      • 14.18.3.3 Regional Market Shares, 2025
      • 14.18.3.4 Business Segment Market Shares, 2025
    • 14.18.4 Product Benchmarking
    • 14.18.5 SWOT Analysis
    • 14.18.6 Strategic Outlook
  • 14.19 Sarepta Therapeutics, Inc.
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2021-2024
      • 14.19.3.2 R&D, 2021-2024
      • 14.19.3.3 Business Segment Market Shares, 2024
    • 14.19.4 Product Benchmarking
    • 14.19.5 SWOT Analysis
    • 14.19.6 Strategic Outlook
  • 14.20 Ultragenyx Pharmaceutical Inc.
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Financial Analysis
      • 14.20.3.1 Net Revenue, 2021-2025
      • 14.20.3.2 R&D, 2021-2025
      • 14.20.3.3 Regional Market Shares, 2025
    • 14.20.4 Product Benchmarking
    • 14.20.5 SWOT Analysis
    • 14.20.6 Strategic Outlook
  • 14.21 Vertex Pharmaceuticals Incorporated
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2021-2025
      • 14.21.3.2 R&D, 2021-2025
      • 14.21.3.3 Regional Market Shares, 2024
    • 14.21.4 Product Benchmarking
    • 14.21.5 SWOT Analysis
    • 14.21.6 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players
Show more
Product Code: PHA1385

List of Tables

  • Table 1 Cell & Gene Therapy Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
  • Table 2 Cell & Gene Therapy Market: International Trade Tariff Impact Recovery Scenarios Snapshot
  • Table 3 Cell & Gene Therapy Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
  • Table 4 Cell & Gene Therapy Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
  • Table 5 Cell & Gene Therapy Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
  • Table 6 Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 7 Cell & Gene Therapy Market Forecast by Cell Therapy, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 8 Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 9 Stem Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 10 CAR-T Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 11 TCR-T Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 12 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 13 Cell & Gene Therapy Market Forecast by Gene Therapy, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 14 Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 15 Gene Augmentation Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 16 Gene Inhibition Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 17 Gene Editing Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 18 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 19 Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 20 Oncology Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 21 Genetic Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 22 Cardiovascular Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 23 Neurological Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 24 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 25 Ophthalmic Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 26 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 27 Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 28 Cell & Gene Therapy Market Forecast by Viral Vectors, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 29 Viral Vectors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 30 Retrovirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 31 Lentivirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 32 Adenovirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 33 AAV Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 34 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 35 Non-viral vectors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 36 Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 37 Hospitals Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 38 Research Institutes Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 39 Pharmaceutical Companies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 40 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 41 Cell & Gene Therapy Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 42 North America Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 43 North America Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 44 North America Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 45 North America Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 46 North America Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 47 U.S. Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 48 Canada Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 49 Europe Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 50 Europe Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 51 Europe Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 52 Europe Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 53 Europe Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 54 Germany Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 55 France Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 56 UK Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 57 Italy Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 58 Spain Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 59 Russia Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 60 Rest of Europe Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 61 Asia-Pacific Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 62 Asia Pacific Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 63 Asia Pacific Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 64 Asia Pacific Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 65 Asia Pacific Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 66 Japan Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 67 China Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 68 India Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 69 Australia Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 70 South Korea Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 71 Singapore Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 72 Rest of Asia Pacific Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 73 Latin America Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 74 Latin America Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 75 Latin America Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 76 Latin America Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 77 Latin America Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 78 Brazil Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 79 Mexico Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 80 Argentina Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 81 Rest of Latin America Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 82 MEA Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 83 MEA Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 84 MEA Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 85 MEA Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 86 MEA Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 87 GCC Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 88 South Africa Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 89 Rest of the MEA Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 90 Strategic Outlook
  • Table 91 Adaptimmune: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Adaptimmune: Product Benchmarking
  • Table 93 Adaptimmune: SWOT Analysis
  • Table 94 Adaptimmune: Strategic Outlook
  • Table 95 ALLOGENE THERAPEUTICS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 ALLOGENE THERAPEUTICS: Product Benchmarking
  • Table 97 ALLOGENE THERAPEUTICS: SWOT Analysis
  • Table 98 ALLOGENE THERAPEUTICS: Strategic Outlook
  • Table 99 Atara Biotherapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Atara Biotherapeutics: Product Benchmarking
  • Table 101 Atara Biotherapeutics: SWOT Analysis
  • Table 102 Atara Biotherapeutics: Strategic Outlook
  • Table 103 Beam Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 Beam Therapeutics: Product Benchmarking
  • Table 105 Beam Therapeutics: SWOT Analysis
  • Table 106 Beam Therapeutics: Strategic Outlook
  • Table 107 BioMarin: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 BioMarin: Product Benchmarking
  • Table 109 BioMarin: SWOT Analysis
  • Table 110 BioMarin: Strategic Outlook
  • Table 111 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 112 Bristol-Myers Squibb Company: Product Benchmarking
  • Table 113 Bristol-Myers Squibb: SWOT Analysis
  • Table 114 Bristol-Myers Squibb: Strategic Outlook
  • Table 115 Catalent, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Catalent, Inc: Product Benchmarking
  • Table 117 Catalent, Inc: SWOT Analysis
  • Table 118 Catalent, Inc: Strategic Outlook
  • Table 119 CRISPR Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 120 CRISPR Therapeutics: Product Benchmarking
  • Table 121 CRISPR Therapeutics: SWOT Analysis
  • Table 122 CRISPR Therapeutics: Strategic Outlook
  • Table 123 Genetix Biotherapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 Genetix Biotherapeutics Inc.: Product Benchmarking
  • Table 125 Genetix Biotherapeutics Inc.: SWOT Analysis
  • Table 126 GenScript: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 GenScript: Product Benchmarking
  • Table 128 GenScript: SWOT Analysis
  • Table 129 Genetix Biotherapeutics Inc.: Strategic Outlook
  • Table 130 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 131 Gilead Sciences, Inc.: Product Benchmarking
  • Table 132 Gilead Sciences, Inc.: SWOT Analysis
  • Table 133 Gilead Sciences, Inc.: Strategic Outlook
  • Table 134 Intellia Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 135 Intellia Therapeutics, Inc.: Product Benchmarking
  • Table 136 Intellia Therapeutics, Inc.: SWOT Analysis
  • Table 137 Intellia Therapeutics, Inc.: Strategic Outlook
  • Table 138 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 139 Johnson & Johnson: Product Benchmarking
  • Table 140 Johnson & Johnson: SWOT Analysis
  • Table 141 Johnson & Johnson: Strategic Outlook
  • Table 142 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 143 Lonza: Product Benchmarking
  • Table 144 Lonza: SWOT Analysis
  • Table 145 Lonza: Strategic Outlook
  • Table 146 MeiraGTx Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 147 MeiraGTx Limited: Product Benchmarking
  • Table 148 MeiraGTx Limited: SWOT Analysis
  • Table 149 MeiraGTx Limited: Strategic Outlook
  • Table 150 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 151 Novartis AG: Product Benchmarking
  • Table 152 Novartis AG: SWOT Analysis
  • Table 153 Novartis AG: Strategic Outlook
  • Table 154 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 155 Sarepta Therapeutics, Inc.: Product Benchmarking
  • Table 156 Sarepta Therapeutics, Inc.: SWOT Analysis
  • Table 157 Sarepta Therapeutics, Inc.: Strategic Outlook
  • Table 158 Ultragenyx Pharmaceutical Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 159 Ultragenyx Pharmaceutical Inc.: Product Benchmarking
  • Table 160 Ultragenyx Pharmaceutical Inc.: SWOT Analysis
  • Table 161 Ultragenyx Pharmaceutical Inc.: Strategic Outlook
  • Table 162 Vertex Pharmaceuticals Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 163 Vertex Pharmaceuticals Incorporated: Product Benchmarking
  • Table 164 Vertex Pharmaceuticals Incorporated: SWOT Analysis
  • Table 165 Vertex Pharmaceuticals Incorporated: Strategic Outlook

List of Figures

  • Figure 1 Cell & Gene Therapy Market Segmentation
  • Figure 2 Cell & Gene Therapy Market by Therapy Type: Market Attractiveness Index
  • Figure 3 Cell & Gene Therapy Market by Indication: Market Attractiveness Index
  • Figure 4 Cell & Gene Therapy Market by Vector Type: Market Attractiveness Index
  • Figure 5 Cell & Gene Therapy Market by End User: Market Attractiveness Index
  • Figure 6 Cell & Gene Therapy Market Attractiveness Index by Region
  • Figure 7 Cell & Gene Therapy Market: Market Dynamics
  • Figure 8 Cell & Gene Therapy Market: Impact Analysis
  • Figure 9 Cell & Gene Therapy Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 10 Cell & Gene Therapy Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 11 Cell & Gene Therapy Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 12 Short Term & Long Term Planning
  • Figure 13 Impact of U.S. and China Trade War
  • Figure 14 Most Impacted Countries
  • Figure 15 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • Figure 16 Cell & Gene Therapy Market: Porter's Five Forces Analysis
  • Figure 17 Cell & Gene Therapy Market: PEST Analysis
  • Figure 18 Cell & Gene Therapy Market by Therapy Type: Market Attractiveness Index
  • Figure 19 Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 20 Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026, 2031, 2036 (%)
  • Figure 21 Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 22 Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 23 Stem Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 24 Stem Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 25 CAR-T Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 26 CAR-T Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 27 TCR-T Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 28 TCR-T Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 29 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 30 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 31 Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 32 Gene Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 33 Gene Augmentation Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 34 Gene Augmentation Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 35 Gene Inhibition Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 36 Gene Inhibition Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 37 Gene Editing Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 38 Gene Editing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 39 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 40 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 41 Cell & Gene Therapy Market by Indication: Market Attractiveness Index
  • Figure 42 Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 43 Cell & Gene Therapy Market Share Forecast by Indication, 2026, 2031, 2036 (%)
  • Figure 44 Oncology Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 45 Oncology Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 46 Genetic Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 47 Genetic Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 48 Cardiovascular Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 49 Cardiovascular Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 50 Neurological Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 51 Neurological Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 52 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 53 Infectious Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 54 Ophthalmic Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 55 Ophthalmic Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 56 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 57 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 58 Cell & Gene Therapy Market by Vector Type: Market Attractiveness Index
  • Figure 59 Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 60 Cell & Gene Therapy Market Share Forecast by Vector Type, 2026, 2031, 2036 (%)
  • Figure 61 Viral Vectors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 62 Viral Vectors Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 63 Retrovirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 64 Retrovirus Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 65 Lentivirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 66 Lentivirus Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 67 Adenovirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 68 Adenovirus Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 69 AAV Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 70 AAV Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 71 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 72 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 73 Non-viral vectors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 74 Non-viral vectors Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 75 Cell & Gene Therapy Market by End-user: Market Attractiveness Index
  • Figure 76 Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
  • Figure 77 Cell & Gene Therapy Market Share Forecast by End-user, 2026, 2031, 2036 (%)
  • Figure 78 Hospitals Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 79 Hospitals Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 80 Research Institutes Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 81 Research Institutes Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 82 Pharmaceutical Companies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 83 Pharmaceutical Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 84 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 85 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 86 Cell & Gene Therapy Market Forecast by Region 2025 and 2035 (Revenue, CAGR%)
  • Figure 87 Cell & Gene Therapy Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 88 Cell & Gene Therapy Market by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 89 North America Cell & Gene Therapy Market Attractiveness Index
  • Figure 90 North America Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 91 North America Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 92 North America Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 93 North America Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 94 North America Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
  • Figure 95 North America Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 96 North America Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 97 North America Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 98 North America Cell & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
  • Figure 99 North America Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
  • Figure 100 North America Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
  • Figure 101 U.S. Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 102 Canada Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 103 Europe Cell & Gene Therapy Market Attractiveness Index
  • Figure 104 Europe Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 105 Europe Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 106 Europe Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 107 Europe Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 108 Europe Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
  • Figure 109 Europe Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 110 Europe Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 111 Europe Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 112 Europe Cell & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
  • Figure 113 Europe Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
  • Figure 114 Europe Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
  • Figure 115 Germany Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 116 France Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 117 UK Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 118 Italy Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 119 Spain Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 120 Russia Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 121 Rest of Europe Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 122 Asia Pacific Cell & Gene Therapy Market Attractiveness Index
  • Figure 123 Asia Pacific Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 124 Asia Pacific Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 125 Asia Pacific Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 126 Asia Pacific Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 127 Asia Pacific Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
  • Figure 128 Asa Pacific Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 129 Asia Pacific Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 130 Asia Pacific Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 131 Asia Pacific Cell & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
  • Figure 132 Asia Pacific Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
  • Figure 133 Asia Pacific Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
  • Figure 134 Japan Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 135 China Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 136 India Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 137 Australia Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 138 South Korea Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 139 Singapore Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 140 Rest of Asia Pacific Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 141 Latin America Cell & Gene Therapy Market Attractiveness Index
  • Figure 142 Latin America Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 143 Latin America Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 144 Latin America Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 145 Latin America Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 146 Latin America Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
  • Figure 147 Latin America Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 148 Latin America Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 149 Latin America Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 150 Latin America Cell & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
  • Figure 151 Latin America Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
  • Figure 152 Latin America Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
  • Figure 153 Brazil Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 154 Mexico Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 155 Argentina Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 156 Rest of Latin America Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 157 MEA Cell & Gene Therapy Market Attractiveness Index
  • Figure 158 MEA Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 159 MEA Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 160 MEA Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 161 MEA Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 162 MEA Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
  • Figure 163 MEA Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
  • Figure 164 MEA Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 165 MEA Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 166 MEA & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
  • Figure 167 MEA Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
  • Figure 168 MEA Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
  • Figure 169 GCC Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 170 South Africa Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 171 Rest of the MEA Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 172 Cell & Gene Therapy Market: Company Share/Ranking, 2026
  • Figure 173 Adaptimmune: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 174 Adaptimmune: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 175 ALLOGENE THERAPEUTICS: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 176 ALLOGENE THERAPEUTICS: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 177 Atara Biotherapeutics: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 178 Atara Biotherapeutics: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 179 Beam Therapeutics: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 180 Beam Therapeutics: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 181 BioMarin: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 182 BioMarin: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 183 BioMarin: Regional Market Shares, 2025
  • Figure 184 Bristol-Myers Squibb Company.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 185 Bristol-Myers Squibb Company: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 186 Bristol-Myers Squibb Company: Regional Market Shares, 2024
  • Figure 187 Bristol-Myers Squibb Company: Business Segment Market Shares, 2024
  • Figure 188 Catalent Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 189 Catalent Inc: Regional Market Shares, 2024
  • Figure 190 Catalent Inc: Business Segment Market Shares, 2024
  • Figure 191 CRISPR Therapeutics.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 192 CRISPR Therapeutics.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 193 GenScript.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 194 GenScript: Regional Market Shares, 2024
  • Figure 195 GenScript: Business Segment Market Shares, 2025
  • Figure 196 Gilead Sciences, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 197 Gilead Sciences, Inc.: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 198 Gilead Sciences, Inc.: Regional Market Shares, 2025
  • Figure 199 Gilead Sciences, Inc.: Business Segment Market Shares, 2025
  • Figure 200 Intellia Therapeutics, Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 201 Intellia Therapeutics, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 202 Johnson & Johnson.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 203 Johnson & Johnson: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 204 Johnson & Johnson: Regional Market Shares, 2025
  • Figure 205 Johnson & Johnson: Business Segment Market Shares, 2025
  • Figure 206 Lonza: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 207 Lonza: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 208 Lonza: Regional Market Shares, 2024
  • Figure 209 Lonza: Business Segment Market Shares, 2024
  • Figure 210 MeiraGTx Limited: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 211 MeiraGTx Limited: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 212 Novartis AG.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 213 Novartis AG: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 214 Novartis AG: Regional Market Shares, 2025
  • Figure 215 Novartis AG: Business Segment Market Shares, 2025
  • Figure 216 Sarepta Therapeutics, Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 217 Sarepta Therapeutics, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 218 Sarepta Therapeutics, Inc.: Business Segment Market Shares, 2024
  • Figure 219 Ultragenyx Pharmaceutical Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 220 Ultragenyx Pharmaceutical Inc.: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 221 Ultragenyx Pharmaceutical Inc.: Regional Market Shares, 2025
  • Figure 222 Vertex Pharmaceuticals Incorporated: Net Revenue, 2021-2025 (US$ Million, AGR%)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!